Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 17/20 | 0.62 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773413 | 0.94 | EGLN1 (0.54) | EGLN1 | |
| SCHEMBL1773271 | 0.94 | EGLN1 (0.55) | EGLN1 | |
| SCHEMBL20537163 | 0.93 | EGLN1 (0.52) | EGLN1 | |
| SCHEMBL1772518 | 0.93 | EGLN1 (0.52) | EGLN1 | |
| SCHEMBL12650070 | 0.93 | EGLN1 (0.52) | EGLN1 | |
| SCHEMBL12602111 | 0.93 | EGLN1 (0.52) | EGLN1 | |
| SCHEMBL1773070 | 0.92 | EGLN1 (0.53) | EGLN1HRH3 | |
| SCHEMBL12002506 | 0.92 | EGLN1 (0.56) | EGLN1 | |
| SCHEMBL1773000 | 0.92 | EGLN1 (0.54) | EGLN1 | |
| SCHEMBL1772698 | 0.92 | EGLN1 (0.50) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210008069-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-01-14 | — | — | US | disclosed |
| US-20190151315-A1 | Drug For Preventing Or Treating Lactic Acidosis | KEIO UNIVERSITY (JP) | 2019-05-23 | — | — | US | disclosed |
| US-20190000847-A1 | THERAPEUTIC AGENT FOR A WOUND | DAIICHI SANKYO COMPANY LIMITED (JP) | 2019-01-03 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008069-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | SLC10A2, FABP2, SI | EGLN1 959/4885FFAR4 776/4885HRH3 303/4885 |
| US-20190151315-A1 | Drug For Preventing Or Treating Lactic Acidosis | LDHA, LDHB, SLC16A1 | EGLN1 301/4885FFAR4 522/4885HRH3 897/4885 |
| US-20190000847-A1 | THERAPEUTIC AGENT FOR A WOUND | MMP8, CCL11, C3AR1 | EGLN1 370/4885FFAR4 2191/4885HRH3 537/4885 |
| US-20110112103-A1 | 5-HYDROXYPYRIMIDINE-4-CARBOXAMIDE COMPOUND | EPOR, CBR1, CBR3 | EGLN1 16/4885FFAR4 1739/4885HRH3 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.